- All
- Adalimumab
- iDose
- Infliximab
- Intravenous
- Mirikizumab
- Subcutaneous
- T3
- Testimonial
- Ustekinumab
- Vedolizumab
- Walkthrough
- Webinar
Using iDose: Scenario 3 – Forecasting the Transition to Subcutaneous Vedolizumab
See how iDose can be used to forecast the transition from IV induction to subcutaneous vedolizumab in a patient with…
Using iDose Scenario 2 – Forecasting the Transition to Subcutaneous Mirikizumab
See how iDose can be used to forecast the transition from IV induction to subcutaneous mirikizumab in a patient with moderate ulcerative colitis. The walkthrough models concentrations across multiple subcutaneous doses to show how the patient may progress toward the selected target trough over time. It also demonstrates how patient-specific factors, including albumin, can change the predicted clearance and dosing forecast.
Using iDose: Scenario 1 – Forecasting Initial Infliximab Dosing
See how iDose can be used before the first infliximab dose to forecast drug exposure in a patient with severe…
Combining Bedside and Clinical Research Data to Inform Disease Progression and Outcomes
Baysient's Founder and Chief Science Officer, Diane Mould, Ph.D., speaks in the 2025-26 Pediatric Clinical Pharmacology Lecture Series hosted by…
Adalimumab Adult Dosing
Learn how Baysient’s T3 application helps physicians optimize Adalimumab dosing for adult patients. This walkthrough demonstrates how T3 provides personalized…
Adalimumab Pediatric Dosing
See how Baysient’s T3 application supports precision dosing for pediatric patients on Adalimumab. In this walkthrough, we demonstrate how T3…
Ustekinumab Dosing for a 70 kg Patient
Learn how Baysient’s T3 application empowers gastroenterologists to optimize Ustekinumab treatment. This walkthrough demonstrates how T3 provides personalized dosing insights…
Vedolizumab IV Dosing for a 20 kg Patient
Learn how Baysient’s T3 application customizes Vedolizumab IV dosing for smaller patients. This video demonstrates how T3 uses patient-specific data…
Vedolizumab IV Dosing for an 80 kg Patient
Watch how Baysient’s T3 application supports precision dosing for Vedolizumab IV therapy. In this video, we walk through a case…
Subcutaneous Infliximab Dosing for a 70 kg Patient
Discover how Baysient’s T3 application enables gastroenterologists to personalize subcutaneous Infliximab therapy for smaller patients with lower weights. In this…
Subcutaneous Infliximab Dosing for a 90 kg Patient
See how Baysient’s T3 application enables gastroenterologists to personalize subcutaneous Infliximab therapy for patients around 90 kg. In this walkthrough,…
Infliximab IV Dosing for a 20 kg Patient
See how Baysient’s T3 application supports precision dosing for a 20 kg patient on Infliximab IV therapy. This walkthrough demonstrates…
Infliximab IV Dosing for an 80 kg Patient
Learn how Baysient’s T3 application simplifies Infliximab IV dosing for an 80 kg adult patient. In this video walkthrough, we…
Clinician Testimonial: Improving IBD Patient Outcomes with iDose
Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like infliximab, has long been challenged by issues such as antibody…
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
